Latest Synuclein Stories
AFFiRiS AG presents Phase I data on a first-of-its-kind treatment with support from The Michael J.
EU support boosts development of therapeutic vaccines against Parkinson's and Multiple System Atrophy.
NEW YORK, April 23, 2014 /PRNewswire-USNewswire/ -- The Michael J.
NEW YORK, Feb. 25, 2014 /PRNewswire-USNewswire/ -- The Parkinson's Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J.
The most devastating aspect of Parkinson's disease may not be its debilitating symptoms, which rob its victims of their ability to control their own movement.
Researchers at Tel Aviv University (TAU) say an artificial sweetener could be a potential treatment for Parkinson's disease.
A protein known to be a key player in the development of Parkinson's disease is able to enter and harm cells in the same way that viruses do.
Researchers from Tel Aviv University describe experiments that could lead to a new approach for treating Parkinson's disease (PD) using a common sweetener, mannitol.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells.
- A poem in which the author retracts something said in an earlier poem.